DNLI
Denali Therapeutics Inc.
Next earnings Aug 10, 2026 · consensus $-0.68 EPS, $15.7M rev
Last earnings -3.4% on 2026-05-07
$24.82
▲ 0.00%$24.82▲ +77.16%
over 1Y
L $12.75EODHDH $24.82
Earnings Dividend Split Congress buy Congress sellFilings colored by tone · hover for detail
Today+0.0%
1W+13.0%
1M+27.8%
3M+18.1%
YTD+52.2%
1Y+76.8%
Hold
Conviction
Horizon
Medium (3–12mo)
Street · 25 analysts
Strong Buy
Conservative balance sheet (liabilities/equity 0.13x).
Denali Therapeutics Inc. shows $0.00 in FY2025 revenue, and -50.6% ROE.
Sources: SEC EDGAR (CIK 0001714899, latest 10-Q filed 2026-05-07) · EODHD · as of 6/24/2026, 8:29:16 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.